MDS 2023 | The role of menin inhibitors in the treatment of HR-MDS and AML
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the role of menin inhibitors in the treatment of high-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML). Dr Stein explains that menin inhibitors are most effective in patients who have a rearrangement of the MLL gene, which is not common in patients with MDS. Dr Stein further notes that patients with relapsed or refractory (R/R) AML and who have a lower blast percentage may be candidates for menin inhibitor treatment, but resistance is common. To conclude, Dr Stein suggests that, going forward, menin inhibitors could be used in combination with an agent that acts broadly on leukemia to more effectively treat patients with HR-MDS and AML. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Astellas Pharmaceutical, Agios Pharmaceuticals, and Genentech: Consultancy, Membership on an entity’s Board of Directors or advisory committees; PTC Therapeutics and Syros: Membership on an entity’s Board of Directors or advisory committees; Syndax: Consultancy, Research Funding; Amgen, AbbVie, Seattle Genetics, and Biotheryx: Consultancy; Daiichi-Sankyo, Celgene Pharmaceuticals, and Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Auron Therapeutics: Current equity holder in private company; PinotBio, Bristol Myers Squibb, Jazz Pharmaceuticals, Foghorn Therapeutics, Blueprint Medicines, Gilead Sciences, Janssen Pharmaceuticals: Consultancy; Bayer: Research Funding.
